Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes |
Synonyms | |
Therapy Description |
LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes are T-cells that recognize the Epstein-Barr virus proteins LMP, BARF1, and EBNA1, potentially resulting in increased anti-tumor immune response against cells expressing these proteins (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes | LMP/BARF1/EBNA1-specific CTLs|LMP1/BARF1/EBNA-1 MABEL CTLs | LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes are T-cells that recognize the Epstein-Barr virus proteins LMP, BARF1, and EBNA1, potentially resulting in increased anti-tumor immune response against cells expressing these proteins (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02287311 | Phase I | LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | Recruiting | USA | 0 |